文献速递类风湿关节炎

新获批药物观察到的安全性是否比已确立药物更差?类风湿关节炎免疫调节药物关键安全性结局风险时间趋势研究

Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2025-02-17

这项2006至2022年瑞典全国注册队列研究纳入33550例b/tsDMARD起始治疗者、16011例早期未用过生物制剂RA队列及111074例匹配一般人群,主要结局为主要不良心血管事件、静脉血栓栓塞、癌症或严重感染中任一首次发生。b/tsDMARD在该类药物上市超过5年(对比不足2年)起始与较低结局发生率相关(未调整HR=0.74,95%CI=0.67-0.81),调整患者特征后关联减弱(调整HR=0.93,95%CI=0.84-1.03);2016-2021年起始对比2006-2010年起始的调整HR=0.74(95%CI=0.69-0.80),而背景人群发生率保持恒定。作者认为轻度通道偏倚使新上市b/tsDMARD安全性显得更差,近年RA典型合并症发生率下降提示新b/tsDMARD可接受安全性门槛应降低。

要点

  • b/tsDMARD上市超过5年对比不足2年起始:未调整HR=0.74(95%CI=0.67-0.81),调整后HR=0.93(95%CI=0.84-1.03)。
  • 2016-2021年对比2006-2010年起始b/tsDMARD:调整HR=0.74(95%CI=0.69-0.80),背景人群发生率恒定。
  • 作者认为轻度通道偏倚使新上市b/tsDMARD安全性显得更差,可接受安全性门槛应降低。

核心结论

  • 轻度通道偏倚使b/tsDMARD新上市时的安全性表现更差。
  • 近年b/tsDMARD起始者中典型RA合并症发生率下降,作者认为新b/tsDMARD可接受安全性门槛应降低。

研究设计与样本

  • 2006至2022年瑞典全国注册队列研究,数据来自瑞典风湿病质量注册及国家注册。
  • 纳入b/tsDMARD起始治疗33550次、早期未用过生物制剂RA队列16011例、匹配一般人群队列111074例。
  • 主要结局为主要不良心血管事件、静脉血栓栓塞、癌症或严重感染中任一首次发生。
  • 按治疗开始时各b/tsDMARD类别上市后时间和起始日历年分层,用Cox回归计算发生率(IR)和风险比(HR)并调整患者特征。

主要发现

  • b/tsDMARD起始队列共观察5862例事件。
  • b/tsDMARD在该类别上市超过5年对比不足2年起始:未调整HR=0.74(95%CI=0.67-0.81)。
  • 调整患者特征后,上市超过5年对比不足2年起始:调整HR=0.93(95%CI=0.84-1.03)。
  • 2016-2021年对比2006-2010年起始b/tsDMARD:调整HR=0.74(95%CI=0.69-0.80),背景人群发生率保持恒定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate rates of key safety outcomes in patients with rheumatoid arthritis (RA) initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and in reference cohorts, presented over time since the market entry of each b/tsDMARD class and over calendar period at treatment start. METHODS: This was a nationwide register-based cohort study conducted from 2006 to 2022. From the Swedish Rheumatology Quality Register and national registers, we identified treatment initiators of b/tsDMARDs (n = 33,550 initiations), an early bionaive RA cohort (n = 16,011), and a matched general population cohort (n = 111,074). The main outcome was first of either major adverse cardiovascular event, venous thromboembolism, cancer, or serious infection. We stratified rates by time since market entry of each b/tsDMARD class at treatment start, and by calendar year of treatment start. We calculated incidence rates (IRs) and hazard ratios (HRs) using Cox regression and adjusted for patient characteristics. RESULTS: Overall, 5862 events were observed in the b/tsDMARD initiator cohort. b/tsDMARD treatments initiated >5 (vs <2) years since market entry of that class were associated with lower outcome rates (unadjusted HR = 0.74; 95% CI = 0.67-0.81). This association was attenuated once adjusting for patient characteristics (adjusted HR = 0.93; 95% CI = 0.84-1.03). By contrast, during our study period, adjusted rates declined (adjusted HR = 0.74 and 95% CI = 0.69-0.80 for b/tsDMARDs initiated 2016-2021 vs 2006-2010), despite a constant rate in the background population. CONCLUSIONS: Modest channelling makes the safety profile of b/tsDMARDs appear worse when new on the market. Declining incidences of typical RA comorbidities in b/tsDMARD initiators during recent years suggest that the bar defining an "acceptable" safety profile for new b/tsDMARDs for use in RA should be lower(ed).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Molander V, Bower H, Frisell T, et al. Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis. Ann Rheum Dis. 2025. PMID: 39966039. doi:10.1016/j.ard.2025.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。